LEP and metabolic syndrome: To determine whether dyslipidemia could contribute to preventing leptin for glucose-lowering effects in insulin-deficient RIP-CreΔLEPR mice, we first measured circulating FFAs, ketone bodies, glycerol, and TG in RIP-CreΔLEPR-LEP at 10 days after the beginning of leptin administration.